Clinical Trial Detail

NCT ID NCT03552029
Title Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Daiichi Sankyo, Inc.
Indications

acute myeloid leukemia

Therapies

Milademetan Tosylate + Quizartinib

Age Groups: senior adult

Additional content available in CKB BOOST